Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avricore Health Inc V.AVCR

Alternate Symbol(s):  AVCRF

Technology Diagnostics & Research Information Technology Services
Avricore Health Inc. is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care. The Company is involved in the business of health data and point-of-care technologies (POCT). HealthTab, its flagship offering, is a turnkey point-of-care testing solution that combines point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). The HealthTab also has capabilities for bacterial and viral tests, such as strep and COVID-19. The HealthTab platform transforms pharmacies into community point-of-care diagnostic centers.


TSXV:AVCR - Post by User

Avricore Health Inc
Bullboard Posts
User Avatar Image
(3)
•••
Comment by guyf1963on Jan 29, 2016 11:22am
200 Views
Post# 24505605

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Got A Question For Everyone

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Got A Question For EveryoneUbisur, my theory is as follows. Lot of investors believe that Q4 will show revenue in excess of $600K, but ain't a given. How would you like to exercise hundred of thousands of warrants that are set at a premium over open market. Why risk buying above open market if revenues have yet been released, those could simply buy in the open market at 0.44 and save some cash. If those can keep the lid on until Q4 are released, then they do not need to front this cash now, IMO they would be glad to buy them if Q4 shows good revenue, but there is still a bit of uncertainty.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities